… ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate … Ionis Pharmaceuticals ProQR receives exclusive worldwide license for IONIS-RHO-2.5 Rx , now QR-1123, for autosomal … the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly “IONIS-RHO-2.5 Rx ”), an RNA …
… ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly Companies … N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lilly and …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board.
ProQR invented an entirely new way to treat genetic diseases. Axiomer enables RNA base editing by recruiting ADAR so your own body can treat disease. Learn more here.
ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need.
… assets. ProQR continues to execute on its global licensing and research partnership with Eli Lilly, focused on … Carreño was most recently Global Business Development & Licensing Head (BD&L) in the Ophthalmology franchise at …
… targets identified by Galapagos -- ProQR plans additional licensing, partnering and other strategic relationships for … and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated …
… Eli Lilly and Company (Lilly) and ProQR entered into a licensing and research collaboration related to ProQR’s … payment of $20 million from Lilly related to the Axiomer licensing and research collaboration. Research and …
